BR0215703A - Polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]e til]-aa-dimetil-benzenoacético, procedimento para sua preparação, preparado farmacêutico e seu uso - Google Patents

Polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]e til]-aa-dimetil-benzenoacético, procedimento para sua preparação, preparado farmacêutico e seu uso

Info

Publication number
BR0215703A
BR0215703A BR0215703-9A BR0215703A BR0215703A BR 0215703 A BR0215703 A BR 0215703A BR 0215703 A BR0215703 A BR 0215703A BR 0215703 A BR0215703 A BR 0215703A
Authority
BR
Brazil
Prior art keywords
preparation
benzidimazol
ethoxyethyl
piperidinyl
polymorph
Prior art date
Application number
BR0215703-9A
Other languages
English (en)
Other versions
BRPI0215703B1 (pt
BRPI0215703B8 (pt
Inventor
Aurelio Orjales Venero
Mosquera Pesta A Ramon
Maravillas Bordell Martin
Gonzalo Canal Mori
Haydee Blanco Fuente
Maria Luisa Lucero De Pablo
Victor Rubio Royo
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0215703(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of BR0215703A publication Critical patent/BR0215703A/pt
Publication of BRPI0215703B1 publication Critical patent/BRPI0215703B1/pt
Publication of BRPI0215703B8 publication Critical patent/BRPI0215703B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"POLIMORFO DE áCIDO 4-[2-[1-(2-ETOXIETIL)-1H-BENZIDIMAZOL-2IL]-1-PIPERIDINIL]ET IL]-<244><244>-DIMETIL-BENZENOACéTICO, PROCEDIMENTO PARA SUA PREPARAçãO, PREPARADO FARMACêUTICO E SEU USO". Trata-se do polimorfo de ácido 4-[2-[1-(2-etoxietil)-1H-benzidimazol-2-il]-1-piperidiniletil]-<244><244> dimetil-benzenoacético da fórmula (I), dos procedimentos para a sua preparação, de fórmulas farmacêuticas que contêm o polimorfo 1 e do uso do polimorfo 1 para o tratamento de reações alérgicas e os processos patológicos mediados pela histamina em mamíferos, tal como o homem.
BRPI0215703A 2002-04-19 2002-04-19 polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]etil]-a, a-dimetil-benzenoacético, preparado farmacêutico, e seu uso do polimorfo 1 BRPI0215703B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (3)

Publication Number Publication Date
BR0215703A true BR0215703A (pt) 2005-02-01
BRPI0215703B1 BRPI0215703B1 (pt) 2017-06-27
BRPI0215703B8 BRPI0215703B8 (pt) 2021-05-25

Family

ID=29225789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0215703A BRPI0215703B8 (pt) 2002-04-19 2002-04-19 polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]etil]-a, a-dimetil-benzenoacético, preparado farmacêutico, e seu uso do polimorfo 1

Country Status (31)

Country Link
US (2) US7612095B2 (pt)
EP (1) EP1505066B1 (pt)
JP (1) JP5142448B2 (pt)
KR (1) KR100673140B1 (pt)
CN (1) CN1290843C (pt)
AR (1) AR039423A1 (pt)
AT (1) ATE347550T1 (pt)
AU (1) AU2002255017B2 (pt)
BG (1) BG66302B1 (pt)
BR (1) BRPI0215703B8 (pt)
CA (1) CA2484460C (pt)
CY (2) CY1107564T1 (pt)
CZ (1) CZ305162B6 (pt)
DE (1) DE60216641T2 (pt)
DK (1) DK1505066T3 (pt)
ES (1) ES2278018T3 (pt)
HK (1) HK1072772A1 (pt)
HR (1) HRP20041048B1 (pt)
HU (1) HU230032B1 (pt)
IL (1) IL164645A (pt)
MX (1) MXPA04010313A (pt)
NO (1) NO329327B1 (pt)
NZ (1) NZ536551A (pt)
PA (1) PA8571201A1 (pt)
PE (1) PE20040086A1 (pt)
PT (1) PT1505066E (pt)
SI (1) SI1505066T1 (pt)
SK (1) SK288052B6 (pt)
UA (1) UA76866C2 (pt)
UY (1) UY27762A1 (pt)
WO (1) WO2003089425A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
JP6023054B2 (ja) * 2011-06-30 2016-11-09 パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカＰａｎａｓｏｎｉｃ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｃｏｒｐｏｒａｔｉｏｎ ｏｆ Ａｍｅｒｉｃａ 通信システム、ユーザ端末並びに通信装置
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
EP3327012B1 (en) 2015-07-24 2021-03-17 Urquima, S.A. Crystalline forms of bilastine and preparation methods thereof
EP3170817A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
EP3170816A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
EP3452462A4 (en) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center SOLID STATE FORMS OF 2- [4- (2- {4- [1- (2-ETHOXYETHYL) -1H-BENZIMIDAZOL-2-YL] -1-PIPERIDINYL} ETHYL) PHENYL] -2-METHYLPROPANOIC ACID AND PREPARATION METHOD THEREOF
ES2813561T3 (es) 2017-09-07 2021-03-24 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica en comprimido que comprende bilastina
ES2835287T3 (es) 2017-12-18 2021-06-22 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio
ES2773756R1 (es) * 2017-12-18 2021-04-12 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua
MX2020007692A (es) 2018-01-18 2020-09-14 Faes Farma Sa Composiciones oftalmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificacion.
CA3200779A1 (en) 2020-12-23 2022-06-30 Strusi ORAZIO LUCA A non-micronized bilastine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
CZ20013711A3 (cs) * 1999-04-16 2002-07-17 Dr. Reddy's Research Foundation Nové polymorfní formy antidiabetických činidel, způsob jejich přípravy a farmaceutické prostředky s jejich obsahem
AU765005B2 (en) * 1999-04-23 2003-09-04 Smithkline Beecham Plc Polymorph of 5-(4-(2- (N-methyl-N-( 2-pyridyl)amino) ethoxy)benzyl) thiazolidine-2,4-dione, maleic acid salt

Also Published As

Publication number Publication date
IL164645A0 (en) 2005-12-18
EP1505066A1 (en) 2005-02-09
CA2484460A1 (en) 2003-10-30
MXPA04010313A (es) 2005-06-08
EP1505066B1 (en) 2006-12-06
PT1505066E (pt) 2007-03-30
DE60216641T2 (de) 2007-09-27
HK1072772A1 (en) 2005-09-09
CA2484460C (en) 2009-09-29
CN1628112A (zh) 2005-06-15
JP5142448B2 (ja) 2013-02-13
US20050203141A1 (en) 2005-09-15
SI1505066T1 (sl) 2007-04-30
WO2003089425A1 (es) 2003-10-30
CZ20041122A3 (cs) 2005-03-16
PE20040086A1 (es) 2004-04-27
UA76866C2 (uk) 2006-09-15
SK50202004A3 (sk) 2005-05-05
NO20044999L (no) 2005-01-14
BRPI0215703B1 (pt) 2017-06-27
ATE347550T1 (de) 2006-12-15
CY1107564T1 (el) 2013-03-13
IL164645A (en) 2010-11-30
BG108941A (en) 2005-12-30
PA8571201A1 (es) 2003-12-10
CZ305162B6 (cs) 2015-05-27
NO329327B1 (no) 2010-09-27
HRP20041048A2 (en) 2005-02-28
DE60216641D1 (de) 2007-01-18
HU230032B1 (hu) 2015-05-28
AU2002255017A1 (en) 2003-11-03
BRPI0215703B8 (pt) 2021-05-25
ES2278018T3 (es) 2007-08-01
KR100673140B1 (ko) 2007-01-22
CN1290843C (zh) 2006-12-20
DK1505066T3 (da) 2007-03-19
US7612095B2 (en) 2009-11-03
CY2013015I1 (el) 2015-08-05
NZ536551A (en) 2006-08-31
JP2005529120A (ja) 2005-09-29
KR20050005448A (ko) 2005-01-13
HRP20041048A9 (hr) 2013-01-31
CY2013015I2 (el) 2015-08-05
SK288052B6 (sk) 2013-03-01
HUP0500241A2 (hu) 2005-06-28
HRP20041048B1 (hr) 2013-04-30
US20100004285A1 (en) 2010-01-07
AU2002255017B2 (en) 2008-11-13
BG66302B1 (bg) 2013-03-29
AR039423A1 (es) 2005-02-16
UY27762A1 (es) 2003-09-30

Similar Documents

Publication Publication Date Title
BR0215703A (pt) Polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]e til]-aa-dimetil-benzenoacético, procedimento para sua preparação, preparado farmacêutico e seu uso
CY1109328T1 (el) Ενωσεις θειενοδιβενζοαζουλενιου ως αναστολεις παραγοντα νεκρωσης ογκου
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BR0108678A (pt) Novos compostos
BR0007589A (pt) Inibidores da proliferação de células
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
BRPI0412527A (pt) composto, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica, e, processo para preparar um composto.
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
NO20090327L (no) Nye forbindelser 384
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
BRPI0512253A (pt) composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
BRPI0512986A (pt) novos derivados de hidantoìna
NO20052487L (no) 1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.
BR0315143A (pt) Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
BR0016172A (pt) 4-piridinil-n-acil-l-fenilalaninas
SE9903894D0 (sv) Novel compounds
MY136859A (en) Pyrrolidine derivatives as factor xa inhibitors
BR0110184A (pt) Derivado de piridina-1-óxido, e processo para a sua transformação em compostos farmaceuticamente eficazes
WO2002000183A3 (en) Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
BRPI0410840A (pt) derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
DE60216239T8 (de) Verwendung von Cyclohexenon-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Dysurie

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13, 25 E 32 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/04/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: "INPI NO 52402.002779/2022-92 | 52402.003587/2022-01 ORIGEM: 8A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1013880-90.2022.4.01.3400 ACAO PELO PROCEDIMENTO COMUM COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: HYPERA S.A. E FAES FARMA S.A. REU(S): INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL ? INPI"

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.004947/2022-84 NUP: 00407.013384/2022-71 (REF. 0118882-60.2022-1.00.0000) MEDIDA CAUTELAR INTERESSADOS: EMS S/A DIVISAO HORTOLANDIA E OUTROS. SENTENCA: ?ENTENDO QUE HA PLAUSIBILIDADE NA TESE DE DESRESPEITO A AUTORIDADE DO SUPREMO TRIBUNAL FEDERAL PELA AUTORIDADE RECLAMADA, NA MEDIDA EM QUE DEFERIDO PROVIMENTO LIMINAR QUE ASSEGURA EXCLUSIVIDADE NA EXPLORACAO ECONOMICA DO OBJETO DA PATENTE 0215703-9 C8 POR PRAZO QUE EXCEDE O PRAZO DE 20 (VINTE) ANOS CONTADOS DA DATA DE DEPOSITO (CAPUT DO ART.40 DA LEI NO 9.279/96), DEIXANDO DE OBSERVAR DECISAO DE EFEITO VINCULANTE NA ADI NO 5529 ? ?RELATIVAMENTE AOS DEMAIS ORGAOS DO PODER JUDICIARIO E A ADMINISTRACAO PUBLICA DIR

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.002779/2022-92 SECAO JUDICIARIA DO DISTRITO FEDERAL - 8A VARA FEDERAL PROCESSO 1013880-90.2022.4.01.3400/DF POLO ATIVO: HYPERA S.A. E FAS FARMA S.A. POLO PASSIVO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E EMS S.A. SENTENCA: DESSA FORMA, NAO SE VISLUMBRA NO ATO IMPUGNADO (DESPACHO 16.3 DO INPI) QUALQUER VICIO QUE O MACULE, NAO HAVENDO QUE SE FALAR EM DIREITO ADQUIRIDO A REGIME JURIDICO. ADEMAIS, DIANTE DOS PARAMETROS ESTABELECIDOS PELO STF NA ADI 5.529, NAO E POSSIVEL QUE ESTE JUIZO AMPLIE O PRAZO DE VIGENCIA DA PATENTE PARA ALEM DO PRAZO FIXADO NO CAPUT DO ARTIGO 40 DA LPI.? COM BASE NESSAS PREMISSAS, RECONHECER A IMPROCEDENCIA DA PRETENSAO DA PA